Regulatory9 min read
Bac Water Named in FDA Letters: Where to Buy Now
The FDA now lists bacteriostatic water itself as an unapproved drug when sold beside peptides. What that changes for diluent supply — and what it doesn't.
Peptide News & Analysis
FDA actions, trial readouts, vendor coverage and pricing reports — curated for peptide buyers and clinicians.
Daily Peptide News
New articles delivered to your inbox every morning. Free.
Latest News
Industry11 min read
Peptide Customs Seizures: Why Domestic Now Wins
CBP seized 5,000 peptide shipments, de minimis is dead, and an Oct 22 rule strips FDA-regulated mail of the fast lane. The overseas-vs-domestic math.
Industry10 min read
Fake Peptide Vendor Sites: 5 Checks Before You Buy
We ran whois on 10 peptide vendor domains. Two imitation sites are dead at the registry, one resolves to something else entirely. Here's how to check.
Trials13 min read
NVG-291 Phase 3 Begins: Nerve Repair Peptide Data
NervGen's NVG-291 starts Phase 3 screening after 2.6x GRASSP gains in chronic paralysis. What the nerve peptide is — and what's sourceable instead.
Industry9 min read
Semaglutide Slowed Aging in Mice: 12% Longer Lifespan
A Nature study started semaglutide in 20-month-old mice. Median lifespan rose about 12% and beat calorie restriction on memory. What it does not show.
Industry9 min read
Oral Amylin Pill Posts First Human Data: 3.3% in 24 Days
Structure's ACCG-2671 cut 3.3% body weight from one 10 mg dose with a 6-day half-life. What the first oral amylin data means for peptide buyers.
Industry13 min read
Semaglutide and Asthma: 40% Fewer Attacks, 20% Less COPD
Semaglutide users logged ~40% fewer asthma attacks and 20% fewer COPD flare-ups across four UK cohorts. What the ERS data supports — and what it doesn't.
Regulatory10 min read
Copper Peptide Injections Hit NPR: What the Data Shows
NPR put GHK-Cu injections on national radio September 7. What the human record actually covers, what the February FDA panel decides, and how buyers verify.
Industry10 min read
TrumpRx GLP-1 Prices: What Maintenance Actually Costs
TrumpRx lists semaglutide at $199 and tirzepatide at $299. Both are starter doses — maintenance runs $349 to $449. The full cash-price map.
Industry9 min read
Do Oral Tirzepatide Pills Work? A Class Action Says No
A federal class action says compounded oral tirzepatide tablets have no absorption pathway. What the filing alleges, and the delivery route with real data.
Industry10 min read
GLP-1 Hair Loss: 37% Higher Risk, New Genetic Data
A September 3 genetic study ties GLP-1 receptor activity to male-pattern hair loss — a different mechanism than the shedding seen in July's BMJ cohort.
Regulatory8 min read
FDA Warns 5 Peptide Vendors: Who's Named, What Changes
The FDA posted five peptide-vendor warning letters on September 1, citing retatrutide, tesamorelin and three more. Who was named and what it means.
Industry11 min read
Somatropin vs Peptides: HGH Alternatives
Somatropin is prescription rHGH — no peptide vendor sells it. Here's how it really differs from the GH-axis secretagogues people search for instead.
Trials8 min read
ASC30 Oral GLP-1 Enters Phase 3: 7.7% Weight Loss
Ascletis dosed the first Phase 3 patient on ASC30 — and its oral GLP-1/GIP/amylin triple hit 15.2% in primates. What that means for buyers today.
Industry14 min read
GLP-1s and Libido: Desire Down, Testosterone Up
A meta-analysis of 680 men found GLP-1s raise total testosterone. Two 2026 reviews report desire falling anyway. The SHBG gap, and the 5-HT2C model.
Industry10 min read
ESC Heart Failure Guidelines Back Semaglutide, Tirzepatide
ESC just gave semaglutide and tirzepatide a Class IIa nod in heart failure with obesity, LVEF 45%+. The exact wording, the trials, and what it changes.
Industry14 min read
GLP-1s in IBD: Ulcerative Colitis & Crohn's Data
16,242 IBD patients on GLP-1s show 54% lower surgery odds. The one study designed to strip out confounding found nothing. Both datasets, unpacked.
Regulatory8 min read
Tirzepatide Wins FDA Heart-Risk Label: The Data
FDA cleared tirzepatide to cut major cardiac events in type 2 diabetes. What SURPASS-CVOT's 13,299 patients showed and what it changes for buyers.